Pacira Discloses Two Merger Suits and 15 Demand Letters Over 14D-9 Disclosures
PCRX sits 94% above its 52-week low of $18.8.
Summary
Pacira disclosed two New York state court suits and fifteen demand letters alleging its 14D-9 omitted material information about the $36.50-per-share Viatris merger. The plaintiffs seek to block the deal or win damages; Pacira says the disclosures comply with law.
Key Events · Legal and Risk Events · PCRX
-
Two Merger Suits Filed
Carroll v. Pacira (Index No. 656215/2026) and Burke v. Pacira (Index No. 656243/2026) were filed in New York Supreme Court, naming Pacira and each board member as defendants.
-
Claims and Relief Sought
Plaintiffs allege negligent misrepresentation and concealment over the Schedule 14D-9 and seek to enjoin the deal until omitted information is disclosed, or rescission and damages if it closes.
-
Fifteen Demand Letters Received
Pacira has received fifteen demand letters, including two draft complaints, generally seeking disclosure of information allegedly omitted from the Schedule 14D-9.
-
No Service, No Loss Estimate
The Pacira Defendants have not been served and say they cannot predict the outcome or estimate a possible loss range; they intend to defend the disclosures.
Analysis · PCRX · Life Sciences
Two stockholder suits and fifteen demand letters now challenge the disclosure in Pacira's Schedule 14D-9 for the $36.50-per-share Viatris tender offer. The complaints seek to block the deal until more information is disclosed, or rescission and damages if it closes. Pacira says it will defend the disclosures and cannot estimate a loss range. This is standard merger-objection litigation, but it can delay the tender closing and adds legal cost; the company has not been served yet.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PCRX was trading at $36.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $18.80 to $36.67. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.